Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl DUBLIN and BRIDGEWATER, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascula
Amarin Corporation plc (NASDAQ:AMRN) will present new REDUCE-IT and EPA analyses at the European Society of Cardiology Congress 2026, adding further research around icosapent ethyl, cardiovascular risk factors and potential mechanisms associated with eicosapentaenoic acid. The presentations, scheduled for August 28 through August 30 during the Munich conference, will examine areas including treatment adherence, longer-term outcomes, lipoprotein(a), coagulation biomarkers and cellular pathways re
This is the newest page. Registered accounts read further back.